Tags

Type your tag names separated by a space and hit enter

Mechanisms underlying the protective effect of montelukast in prevention of endometrial hyperplasia in female rats.
Int Immunopharmacol. 2018 Sep; 62:326-333.II

Abstract

OBJECTIVE

To study the possible protective role of montelukast in endometrial hyperplesia (EH) rat model, induced by estradiol valerate (EV).

METHODS/MATERIALS

Thirty six female albino Wistar rats were classified into 7 groups: normal control, EV (2 mg/kg/day, p.o.), montelukast (10 mg/kg/day, p.o.), montelukast (1 mg/kg/day, p.o.) + EV (2 mg/kg/day, p.o.), montelukast (10 mg/kg/day, p.o.) + EV (2 mg/kg/day, p.o.), montelukast (20 mg/kg/day, p.o.) + EV (2 mg/kg/day, p.o.) groups. Uterine malondialdehyde (MDA), superoxide dismutase (SOD), total nitrites (NO) and serum total antioxidant capacity (TAC) were determined. Uterine, serum total cholesterol, high density lipoprotein (HDL) and tumor necrosis factor (TNF)-α were measured. Histopathological examination of the uterine tissue was also done. In addition, immunohistochemistry was done using Phosphatase and tensin homolog (PTEN) and inducible nitric oxide synthase (iNOS) antibodies.

RESULTS

Our results showed that montelukast in dose dependant manner improves oxidative stress, lipids profile and TNF α which were affected by EV. Moreover, immunohistochemical examination revealed that montelukast markedly reduced iNOS expression, while expression of PTEN was markedly enhanced, as compared to EV group. The protective effects of montelukast were also verified histopathologically.

CONCLUSIONS

Montelukast in dose dependant manner provided biochemical and histo-pathological improvement in EV induced EH, through its anti-inflammatory, antioxidant activity and inhibition of iNOS expression with induction of PTEN expression.

Authors+Show Affiliations

Department of Pharmacology, Faculty of Medicine, Minia University, Egypt. Electronic address: walaayehia22@yahoo.com.Department of Obstetrics and Gynecology, Faculty of Medicine, Minia University, Egypt.Department of Pathology, Faculty of Medicine, Minia University, Egypt.Department of Obstetrics and Gynecology, Faculty of Medicine, Minia University, Egypt.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30056375

Citation

Abdelzaher, Walaa Yehia, et al. "Mechanisms Underlying the Protective Effect of Montelukast in Prevention of Endometrial Hyperplasia in Female Rats." International Immunopharmacology, vol. 62, 2018, pp. 326-333.
Abdelzaher WY, Bahaa HA, Toni NDM, et al. Mechanisms underlying the protective effect of montelukast in prevention of endometrial hyperplasia in female rats. Int Immunopharmacol. 2018;62:326-333.
Abdelzaher, W. Y., Bahaa, H. A., Toni, N. D. M., & Sanad, A. S. (2018). Mechanisms underlying the protective effect of montelukast in prevention of endometrial hyperplasia in female rats. International Immunopharmacology, 62, 326-333. https://doi.org/10.1016/j.intimp.2018.07.008
Abdelzaher WY, et al. Mechanisms Underlying the Protective Effect of Montelukast in Prevention of Endometrial Hyperplasia in Female Rats. Int Immunopharmacol. 2018;62:326-333. PubMed PMID: 30056375.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mechanisms underlying the protective effect of montelukast in prevention of endometrial hyperplasia in female rats. AU - Abdelzaher,Walaa Yehia, AU - Bahaa,Haitham Ahmed, AU - Toni,Nisreen D M, AU - Sanad,Ahmad Sameer, Y1 - 2018/07/26/ PY - 2017/12/29/received PY - 2018/05/09/revised PY - 2018/07/10/accepted PY - 2018/7/30/pubmed PY - 2019/1/3/medline PY - 2018/7/30/entrez KW - Endometrial hyperplasia KW - Estradiol valerate KW - Female rats KW - Montelukast SP - 326 EP - 333 JF - International immunopharmacology JO - Int Immunopharmacol VL - 62 N2 - OBJECTIVE: To study the possible protective role of montelukast in endometrial hyperplesia (EH) rat model, induced by estradiol valerate (EV). METHODS/MATERIALS: Thirty six female albino Wistar rats were classified into 7 groups: normal control, EV (2 mg/kg/day, p.o.), montelukast (10 mg/kg/day, p.o.), montelukast (1 mg/kg/day, p.o.) + EV (2 mg/kg/day, p.o.), montelukast (10 mg/kg/day, p.o.) + EV (2 mg/kg/day, p.o.), montelukast (20 mg/kg/day, p.o.) + EV (2 mg/kg/day, p.o.) groups. Uterine malondialdehyde (MDA), superoxide dismutase (SOD), total nitrites (NO) and serum total antioxidant capacity (TAC) were determined. Uterine, serum total cholesterol, high density lipoprotein (HDL) and tumor necrosis factor (TNF)-α were measured. Histopathological examination of the uterine tissue was also done. In addition, immunohistochemistry was done using Phosphatase and tensin homolog (PTEN) and inducible nitric oxide synthase (iNOS) antibodies. RESULTS: Our results showed that montelukast in dose dependant manner improves oxidative stress, lipids profile and TNF α which were affected by EV. Moreover, immunohistochemical examination revealed that montelukast markedly reduced iNOS expression, while expression of PTEN was markedly enhanced, as compared to EV group. The protective effects of montelukast were also verified histopathologically. CONCLUSIONS: Montelukast in dose dependant manner provided biochemical and histo-pathological improvement in EV induced EH, through its anti-inflammatory, antioxidant activity and inhibition of iNOS expression with induction of PTEN expression. SN - 1878-1705 UR - https://www.unboundmedicine.com/medline/citation/30056375/Mechanisms_underlying_the_protective_effect_of_montelukast_in_prevention_of_endometrial_hyperplasia_in_female_rats_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1567-5769(18)30334-5 DB - PRIME DP - Unbound Medicine ER -